Compare Inovio Pharmaceuticals Inc (INO) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vertiv Holdings Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Vertiv Holdings Co trades at $242.7 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 836.3× Inovio Pharmaceuticals Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Vertiv Holdings Co for 39 Days on average.
| INO | VRT | |
|---|---|---|
Market Cap | $112.19M | $93.83B |
Volume | 3,201,278 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $2.65 | $376.23 |
52-Week Low | $0.66 | $149.83 |
Typical Hold Time | 43 Days | 39 Days |
Enterprise Value | $83.51M | $94.06B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Vertiv (VRT) trades at $242.78, down 1.51% on the day, amid a bearish technical signal but strong fundamental momentum. The stock benefits from robust earnings beats, with Q2 2026 EPS of $1.52 exceeding the $1.42 estimate, and revenue growth projections from $10.23B in 2025 to $11.5B in 2026. Analyst sentiment remains overwhelmingly bullish with a 95% buy rating and a $364.94 consensus price target, driven by AI data center demand for power and cooling solutions.
The outlook is positive given Vertiv's strategic positioning in AI infrastructure, though risks include potential securities law investigations noted in recent news and high valuation multiples like a P/E of 55.14. Investors should weigh the company's growth trajectory against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
